KYMR Company Profile and Key Details

Q: Who are the executives of KYMR?

Ms. Karen WeisbachVice President of People & CultureMs. Elaine CaugheyChief Bus. OfficerDr. Jared A. Gollob M.D.Chief Medical OfficerDr. Bruce L. Booth D.Phil., DPHIL, Ph.D.Co-Founder & ChairmanMr. Bruce N. Jacobs CFAChief Financial OfficerKevin DushneySenior Vice President of IT & OperationsMs. Melissa BrodyVice President of Bus. Devel.Mr. Michael J. TodiscoVice President of Accounting & Fin.Dr. Nello Mainolfi M.D., Ph.D.Co-Founder, Pres, Chief Executive Officer & DirectorMs. Ellen V. Chiniara Esq., J.D.Chief Legal Officer & Corporation Sec.Dr. Jeremy G. Chadwick Ph.D.Chief Operating OfficerMr. Vijay SabesanSenior Vice President of Technical Operations

NASDAQ : KYMR

Kymera Therapeutics

$99.45

9.02+9.97%

At Close 4:00 PM

59.02

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Kymera Therapeutics, Inc. (KYMR) stock surged +9.97%, trading at $99.45 on NASDAQ, up from the previous close of $90.43. The stock opened at $92.84, fluctuating between $91.74 and $105.00 in the recent session.

Stock Snapshot

90.43

Prev. Close

8.18B

Market Cap

91.7413

Day Low

-27.78

P/E Ratio

-3.58

EPS (TTM)

-2.35

Cash Flow per Share

92.84

Open

82.26M

Number of Shares

105

Day High

82.62%

Free Float in %

6.75

Book Value

2.87M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jun 22, 2026	92.84	105.00	91.74	99.45	2.89M
Jun 18, 2026	90.68	92.47	89.18	90.43	1.26M
Jun 17, 2026	88.31	91.05	87.62	89.90	1.09M
Jun 16, 2026	85.88	88.09	84.52	87.44	587.93K
Jun 15, 2026	86.27	88.59	84.84	85.59	485.14K
Jun 12, 2026	82.53	88.58	82.53	86.21	625.22K
Jun 11, 2026	78.27	83.50	77.80	82.96	674.48K
Jun 10, 2026	77.44	80.70	75.82	78.23	604.68K
Jun 09, 2026	75.86	77.32	73.05	76.91	748.28K
Jun 08, 2026	74.73	75.33	73.33	73.95	453.69K
Jun 05, 2026	74.36	75.39	72.77	74.13	639.34K
Jun 04, 2026	73.27	75.29	72.66	74.61	752.69K
Jun 03, 2026	70.99	73.94	69.48	73.21	846.88K
Jun 01, 2026	80.66	80.71	77.20	78.47	437.53K
May 29, 2026	81.83	82.92	80.79	81.42	587.07K
May 28, 2026	81.80	82.20	80.36	81.46	316.76K
May 27, 2026	80.60	82.50	80.55	81.70	330.31K
May 26, 2026	79.17	80.78	77.99	80.77	503.07K
May 22, 2026	79.76	81.15	78.32	78.89	549.37K
May 21, 2026	79.46	80.73	78.65	80.61	407.64K

Contact Details

Watertown, MA 02472

United States

https://www.kymeratx.com 857 285 5300

About Company

Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.

Stock Peers

ARGX

26.03+2.97%

argenx SE$903.75 REGN

2.56+0.42%

Regeneron Pharmaceuticals, Inc.$612.50 UTHR

1.70998+0.32%

United Therapeutics Corporation$538.30 MDGL

7.13+1.41%

Madrigal Pharmaceuticals, Inc.$512.88 VRTX

15.16+3.36%

Vertex Pharmaceuticals Incorporated$466.79 KRYS

-4.63-1.33%

Krystal Biotech, Inc.$343.43 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

21.08+7.47%

Praxis Precision Medicines, Inc.$303.39 ALNY

8.32+2.99%

Alnylam Pharmaceuticals, Inc.$286.41 LGND

-12.71-4.62%

Ligand Pharmaceuticals Incorporated$262.17

Company Overview

Kymera Therapeutics, Inc. (NASDAQ:KYMR) closed at $99.45 USD, gaining $9.02 (9.97%) from the previous close of $90.43. The stock is currently mid-range between its 52-week high and low $36.65 and $105.00. With a market capitalization of about $8.18 billion, Kymera Therapeutics, Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~2.03). Key stats such as the average daily volume over the past year has been around 617.46 thousand shares, trading with heavier-than-usual volume. Headquartered in Watertown, MA, Kymera Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Nello Mainolfi, the company employs approximately 208 people and listed since August 21, 2020. Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 15.27%, SMA50 20.69%, SMA200 65.18%). The stock’s 14-day RSI is 77.3 (overbought), while the ATR of 4.67 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -7.74% below its high and over 388.71% above its low. Average 10-day trading volume of 1.26 million shares is significantly above the 3-month average of 616.71 thousand, indicating heightened recent market interest.

Valuation Metrics

Kymera Therapeutics, Inc. trades at a P/E ratio of -28.48, slightly below the S&P 500 average, with a price-to-sales ratio of 162.95 and a price-to-book ratio of 6.46 trading at moderately above to book value. The P/FCF stands at -34.37, also below market averages.

Dividend & Fair Value

Kymera Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.13. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Kymera Therapeutics, Inc. generated EPS of -$3.60 over the past year. Five-year average earnings growth is -26.36%. Wall Street analysts project EPS growth of -8.32% annually over the next five years. The latest quarter delivered EPS of -$0.71. The next quarter is forecast at -$0.78. Next year's EPS is expected at -$25.73. Analyst sentiment is bullish. Analyst rating data shows there are 21 Strong Buy ratings, 22 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $140.00 to $53.00. The high target offers 40.77% upside. The low target suggests -46.71% downside. The mean target is $102.53. This offers 3.1% upside. Kymera Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended April 30, 2026, missed forecasts by -20.22%. The prior quarter beat by 23.78%. Over the last six quarters, Apple has recorded several small beats. These include 15.79% in February 27, 2025.

Shareholding & Insider Activity

Kymera Therapeutics, Inc. has 71.50 million shares outstanding. The public float is 46.96 million shares, elevated short interest at 13.70% of float. This equals 7.75 million shares. The short ratio is 12.29 days. Institutional investors hold 112.83% of the float. Insiders own 2.53%. Atlas Venture Fund X, L.P. holds 828.83 thousand shares, BAKER BROS. ADVISORS LP has 701.33 thousand shares and Mainolfi Nello has 666.20 thousand shares. Over the past six months, insider transactions show net selling. They sold 111.98 thousand shares across 32 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Kymera Therapeutics generated $78.59M in revenue, or $1.35 per share. Gross margin was 95.46%, operating margin -210.62%, and net profit margin -186.99%. Returns are negative, with ROA at -25.52% and ROE at -37.21%.
On valuation metrics, Kymera Therapeutics trades at a P/E of -28.48, P/S of 162.95 and P/B of 6.46. The current ratio is 10.81 and quick ratio is 10.81. Debt-to-equity is 0.05, supported by a cash flow-to-debt ratio of -3.01.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Kymera Therapeutics posted revenue of $78.59M, down slightly from $46.83M in the prior quarter. Gross profit was $75.03M (margin 95.46%). Operating income was - $165.53M (margin -210.6%). Net income was- $146.96M (EPS - $2.52).
The company ended the quarter with $374.88M in cash and short-term investments, a total debt of $84.67M, and net debt of - $25.29M. Total assets were $575.76M, with equity of $394.97M. Financials further reflected weakness, with operating cash flow of - $102.83M, free cash flow of - $137.31M, and capital expenditures of - $34.48M.

Price Forecast & Outlook

Our AI price prediction model suggests that Kymera Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 15.08%, with price expected at $114.45 by July 06, 2026, within a range of $111.01 to $117.78 3-Month Outlook: Projected fall of -28.12%, reaching $71.48 by September 18, 2026, with a range of $67.03 to $75.43. 1-Year Outlook: Projected gain of 24.0%, with price at $123.32 by June 22, 2027, within a range of $119.26 to $127.44.

Key Takeaways

Kymera Therapeutics, Inc. (NASDAQ:KYMR) shares are down -12.43% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Kymera Therapeutics, Inc. trading at a premium to the broader market with a P/E of -28.48. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $75.45, suggesting -24.13% downside. Our AI forecast model points to short-term strength (15.08% over two weeks), a medium-term fall (-28.12% over three months), and a longer-term gain (24.0% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Kymera Therapeutics, Inc. (KYMR) stock price?

Kymera Therapeutics, Inc. (NASDAQ: KYMR) stock price is $99.45 in the last trading session. During the trading session, KYMR stock reached the peak price of $105.00 while $91.74 was the lowest point it dropped to. The percentage change in KYMR stock occurred in the recent session was 9.97% while the dollar amount for the price change in KYMR stock was $9.02.

KYMR's industry and sector of operation?

The NASDAQ listed KYMR is part of Biotechnology industry that operates in the broader Healthcare sector. Kymera Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of KYMR?

Ms. Karen Weisbach
Vice President of People & Culture
Ms. Elaine Caughey
Chief Bus. Officer
Dr. Jared A. Gollob M.D.
Chief Medical Officer
Dr. Bruce L. Booth D.Phil., DPHIL, Ph.D.
Co-Founder & Chairman
Mr. Bruce N. Jacobs CFA
Chief Financial Officer
Kevin Dushney
Senior Vice President of IT & Operations
Ms. Melissa Brody
Vice President of Bus. Devel.
Mr. Michael J. Todisco
Vice President of Accounting & Fin.
Dr. Nello Mainolfi M.D., Ph.D.
Co-Founder, Pres, Chief Executive Officer & Director
Ms. Ellen V. Chiniara Esq., J.D.
Chief Legal Officer & Corporation Sec.
Dr. Jeremy G. Chadwick Ph.D.
Chief Operating Officer
Mr. Vijay Sabesan
Senior Vice President of Technical Operations

How KYMR did perform over past 52-week?

KYMR's closing price is 171.35% higher than its 52-week low of $36.65 where as its distance from 52-week high of $105.00 is -5.29%.

How many employees does KYMR have?

Number of KYMR employees currently stands at 208.

Link for KYMR official website?

Official Website of KYMR is: https://www.kymeratx.com

How do I contact KYMR?

KYMR could be contacted at phone 857 285 5300 and can also be accessed through its website. KYMR operates from 200 Arsenal Yards Boulevard, Watertown, MA 02472, United States.

How many shares of KYMR are traded daily?

KYMR stock volume for the day was 2.87M shares. The average number of KYMR shares traded daily for last 3 months was 617.46K.

What is the market cap of KYMR currently?

The market value of KYMR currently stands at $8.18B with its latest stock price at $99.45 and 82.26M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	208
Beta	2.03
Sales or Revenue	$78.59M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

KYMR Company Profile and Key Details

Kymera Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Company Overview

Valuation Metrics

Earnings & Analyst Outlook

Key Takeaways

Price Forecast & Outlook